GlassScriptPhysician profile
Shawn Michael Gao
NPI 1740424704
$5,508.03
in general payments reported to CMS, 2019-2025
27 companies · $227 in 2025
The $227 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $523 · 2020: $221 · 2021: $708 · 2022: $752 · 2023: $2,538 · 2024: $539 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,303.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $658.36 | 2019-2025 | Renasys Touch, Pico 7, Renasys Go V2 Home |
| Neurocrine Biosciences, INC. | $609.11 | 2019-2024 | Ingrezza |
| Next Science LLC | $555.21 | 2023 | Blastx, Xperience, Surgx |
| Alkermes, INC. | $489.51 | 2022-2024 | Lybalvi, Aristada, Aristada Initio |
| Integra Lifesciences Corporation | $380.04 | 2019-2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Teva Pharmaceuticals USA, INC. | $353.49 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Progenacare Global, LLC | $320.45 | 2023 | |
| Kci USA, INC. | $297.13 | 2019-2020 | |
| Organogenesis INC. | $270.83 | 2021-2024 | Cygnus Dual |
| Acadia Pharmaceuticals INC | $245.56 | 2023 | Nuplazid |
| Acera Surgical, INC. | $208.71 | 2021-2023 | Restrata Wound Matrix |
| Ucb, INC. | $185.28 | 2020-2023 | Fintepla, Briviact, Nayzilam |
| Otsuka America Pharmaceutical, INC. | $166.03 | 2020-2025 | Rexulti, Abilify Asimtufii |
| Lilly USA, LLC | $124.81 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $113.50 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $93.72 | 2023-2024 | Valtoco |
| Kerecis Limited | $77.32 | 2022-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Janssen Pharmaceuticals, INC | $71.71 | 2023 | Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $54.34 | 2021-2024 | Trintellix |
| Hartmann USA, INC. | $48.47 | 2021-2022 | |
| Lundbeck LLC | $39.75 | 2023-2024 | Rexulti |
| Avanir Pharmaceuticals, INC. | $32.19 | 2019-2021 | |
| Aroa Biosurgery Incorporated | $30.05 | 2019 | |
| Vanda Pharmaceuticals INC. | $25.57 | 2021 | |
| Advanced Oxygen Therapy INC. | $22.16 | 2024 | Topical Oxygen Chamber For Extremities |
| Amgen INC. | $18.82 | 2021 | |
| Medline Industries LP | $15.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Gao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.